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Abstract
Background: Gardnerella vaginalis is identified as the predominant colonist of the vaginal tract in women with
bacterial vaginosis. Vaginolysin (VLY) is a protein toxin released by G. vaginalis. VLY possesses cytolytic activity and
is considered as a main virulence factor of G. vaginalis. Inhibition of VLY-mediated cell lysis by antibodies may have
important physiological relevance.
Results: Single-chain variable fragments of immunoglobulins (scFvs) were cloned from two hybridoma cell lines
producing neutralizing antibodies against VLY and expressed as active proteins in E. coli. For each hybridoma, two
variants of anti-VLY scFv consisting of either VL-VH or VH-VL linked with a 20 aa-long linker sequence (G4S)4 were
constructed. Recovery of scFvs from inclusion bodies with subsequent purification by metal-chelate
chromatography resulted in VLY-binding proteins that were predominantly monomeric. The antigen-binding
activity of purified scFvs was verified by an indirect ELISA. The neutralizing activity was investigated by in vitro
hemolytic assay and cytolytic assay using HeLa cell line. Calculated apparent Kd values and neutralizing potency of
scFvs were in agreement with those of parental full-length antibodies. VH-VL and VL-VH variants of scFvs showed
similar affinity and neutralizing potency. The anti-VLY scFvs derived from hybridoma clone 9B4 exhibited high VLY-
neutralizing activity both on human erythrocytes and cervical epithelial HeLa cells.
Conclusions: Hybridoma-derived scFvs with VLY-binding activity were expressed in E. coli. Recombinant anti-VLY
scFvs inhibited VLY-mediated cell lysis. The monovalent scFvs showed reduced affinity and neutralizing potency as
compared to the respective full-length antibodies. The loss of avidity could be restored by generating scFv
constructs with multivalent binding properties. Generated scFvs is the first example of recombinant single-chain
antibodies with VLY-neutralizing activity produced in prokaryote expression system. G. vaginalis caused infections
continue to be a world-wide problem, therefore neutralizing recombinant antibodies may provide novel
therapeutic agents useful in the treatment of bacterial vaginosis and other diseases caused by G. vaginalis.
Background
Gardnerella vaginalis is a facultative anaerobic bacter-
ium of the Bifidobacteriaceae family and the sole mem-
ber of the genus Gardnerella [1]. G. vaginalis is the
predominant microorganism of the vaginal tract in
women with bacterial vaginosis (BV) [2,3]. BV is highly
prevalent, affecting almost one third of women [4].
Being an important medical condition itself, BV is asso-
ciated with several serious adverse outcomes including
preterm birth and infertility [2,5], endometritis [6], and
acquisition of other sexually transmitted infections [7].
Moreover, G. vaginalis has been linked with infections
outside the reproductive system. It has been demon-
strated that G. vaginalis may cause urinary tract infec-
tions in men [8], retinal vasculitis [9], acute hip arthritis
in a renal transplant recipients [10], vertebral osteomye-
litis [11] and bacteremia in a previously healthy man
[12]. These data indicate that G. vaginalis may be more
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that certain strains of G. vaginalis a r ea b l et of o r mb i o -
films [3,13]. The genomic analysis support findings on
G. vaginalis virulence features such as its ability to
adhere to vaginal epithelium, biofilm formation, cyto-
toxic activity and also provides other features important
to the role of G. vaginalis in BV development [14,15].
The main virulence factor of G. vaginalis is the pro-
tein toxin vaginolysin (VLY) [16,17]. The VLY belongs
to the cholesterol-dependent cytolysins (CDCs), a family
of pore-forming toxins [18]. These toxins disrupt plasma
membranes causing cell lysis and are thought to play a
key role in the virulence of bacteria [18]. VLY is a toxin
specific to human cells as it recognizes the complement
regulatory molecule CD59 [17,19,20]. Taken together
the virulence properties of G. vaginalis allow the bac-
teria to adhere to the vaginal epithelium, produce a bio-
film and secrete VLY that leads to cytolysis and tissue
destruction [3].
The high recurrence rate of BV after antibiotic treat-
ment or persistent BV over time [21,22] may prompt
the development and use of recombinant antibodies as
novel therapeutic agents for disease treatment. The
effectiveness of neutralizing recombinant antibodies
against other bacterial toxins, such as pneumolysin,
Shiga toxin, Clostridium difficile toxin A, Salmonella
SpvB toxin, heat-labile toxin from enterotoxigenic E.
coli, botulinum neurotoxin has been demonstrated in
previous studies [23-29]. Recombinant antibodies neu-
tralizing the cytolytic activity of VLY have not yet been
described.
Recently, we have developed a panel of monoclonal
antibodies (MAbs) against VLY and demonstrated the
ability of some MAbs to prevent the lysis of human ery-
throcytes in vitro [30].
In the current study, the hybridomas producing well-
characterized MAbs 9B4 and 23A2 with the most potent
VLY neutralizing activity were selected to construct
recombinant single-chain variable fragments of immu-
noglobulins (scFvs). The scFvs were produced in E. coli,
purified and characterized in comparison with the full-
length parental MAbs. The ability of scFv to inhibit
cytolytic activity of VLY in vitro has been demonstrated.
Construction of recombinant scFv with a potent VLY-
neutralizing activity may be considered as a first step in
developing novel immunotherapeutic tools for the treat-
ment of BV and other diseases caused by G. vaginalis.
Methods
Cloning and expression of anti-VLY scFvs
Total mRNA was isolated from 3 × 10
6 hybridoma cells
producing neutralizing MAbs 9B4 and 23A2 [30]. Hybri-
doma cells were lysed in solution containing guanidine
thiocyanate and extracted with phenol-chloroform at
reduced pH [31]. The first strand of cDNA was prepared
using RevertAid™ H Minus First Strand cDNA Synthesis
Kit (Thermo Scientific Fermentas, Vilnius, Lithuania)
according to manufacturer’s instructions. The cDNA cor-
r e s p o n d i n gt ot h ev a r i a b l er e g i o no fm o u s eI g Gw a s
obtained using sets of specific primers described pre-
viously [32]: 1) Mouse heavy chain constant region primer:
5’-TTAATAGACAGATGGGGGTGTCGTTTTGGC and
mouse heavy chain FR1 region high degenerate primer 5’-
CATATGSARGTNMAGCTGSAGSAGTC; 2) Mouse
kappa chain constant region primer: 5’-TTAGGATA-
CAGTTGGTGCAGCATC and mouse kappa chain FR1
region universal degenerated primer: 5’-CATATG-
GAYATTGTGMTSACMCARWCTMCA. For each chain,
5 separate clones were selected. Cloned DNA fragments
were sequenced and found to be identical in all 5 clones.
In a second PCR round, additional primers designed to
introduce the 20 amino acid (aa)-long linker sequence
(G4S)4 and NdeI/XhoI restriction sites were used. The VL
and VH DNA fragments were fused in different orienta-
tion to result constructions VL-(G4S)4-VH and VH-(G4S)
4-VL, respectively. The polymerase chain reactions (PCR)
were carried out under standard conditions using High
Fidelity PCR Enzyme Mix (Thermo Scientific Fermentas).
The resulted DNA fragments encoding anti-VLY scFv
were introduced by ligation into expression vector pET28a
(+) (Merck, Darmstadt, Germany) digested with restriction
endonucleases NdeI and XhoI (Thermo Scientific Fermen-
tas). The expression plasmids were transfected into E. coli
BL21(DE3) strain. The anti-VLY scFv synthesis was
induced with 0.5 mM IPTG (isopropyl-b-D-thiogalacto-
pyranoside) (Thermo Scientific Fermentas). After induc-
tion, the cell pellet was disrupted by sonication and
centrifuged. The supernatant (soluble fraction) and the
cell pellet (insoluble fraction) were then analyzed by 12.5%
polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions.
Purification of anti-VLY scFvs
E.coli biomass containing anti-VLY scFv was homoge-
nised in 100 ml (ratio 1:10, biomass:buffer) of 0.1 M
Tris-HCl buffer (pH 7.0) with 5 mM EDTA, 0.1% lyso-
zyme, 0.1% Triton X-100, 1 mM phenylmethylsulpho-
nylfluoride (PMSF) and 2-mercaptoethanol. The
homogenizate was stirred for 30 min at room tempera-
ture (RT), sonicated and centrifuged for 25 min at
24,500 g. The pellet was washed twice with 100 ml of 1
M NaCl containing 0.1% Tween 80 and then with 100
ml of distilled water. After each washing cycle, the sus-
pension was centrifuged for 25 min at 24,500 g. The
pellet containing inclusion bodies after the last washing
cycle was solubilised in 10 mM Tris-HCl (pH 7.0) con-
taining 7 M guanidine hydrochloride (GuHCl). The sus-
pension was stirred overnight at 4°C, centrifuged for
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10 mM Tris-HCl buffer (pH 7.0) containing 6 M GuHCl
to the final protein concentration of 1 mg/ml. The rena-
turation of anti-VLY scFvs was performed by adding
CuSO4 solution to the final concentration of 20 μM and
incubation for 1 h at RT. The reaction was stopped by
adding EDTA solution to the final concentration of 10
mM. Protein solution was centrifuged for 25 min at
40,000 g and the supernatant was loaded onto the
Sephadex G-25 column equilibrated with 25 mM Tris-
HCl buffer (pH 8.0) containing 0.25 M Na2SO4.F r a c -
tions with the target protein were collected, pooled and
loaded onto the Ni (II) NTA column (Qiagen, Hilden,
Germany) (loading buffer:2 5m MT r i s - H C l ,p H8 . 0 ) .
The elution was performed with the same buffer supple-
mented with 1 M imidazole. Fractions containing puri-
fied anti-VLY scFv were collected, dialyzed against
buffer containing 20 mM Tris-HCl (pH 8.0), 50 mM
NaCl and sterile filtered for long term storage.
Aliquots of purified scFv (8 μg) were loaded onto
TSK-gel G2000 SWXL column (7.8 × 300 mm) (Tosoh
Bioscience, Tokyo, Japan). Proteins were eluted with 50
mM phosphate buffer (pH 7.2) supplemented with 0.15
M NaCl at a flow rate of 0.5 ml/min, and detected by
UV absorbance at 215 and 280 nm.
The antigen-binding activity of scFv were analysed by
an indirect ELISA as described below.
Determination of the antigen-binding activity of scFvs by
an indirect ELISA
Microtiter plates (Nunc MaxiSorp, Nunc, Rosikilda,
Denmark) were coated with recombinant purified VLY
[30] by adding 100 μl of VLY solution (5 μg/ml) in coat-
ing buffer (50 mM Na-carbonate, pH 9.5) and incuba-
tion overnight at 4°C. The plates were blocked for 1 h
at RT with 2% bovine serum albumin (BSA) in phos-
phate-buffered saline (PBS) and then incubated with
purified scFv for 1 h at RT. After washing, the plates
were incubated for 1 h at RT with anti-His5 MAb (Qia-
gen, Hilden, Germany) diluted 1:1000 in PBS with 0.1%
Tween 20 (PBST) and then incubated for 1 h with goat
anti-mouse IgG labelled with horse-radish peroxidase
(HRP) (BioRad, Richmond, CA, USA) diluted 1:2000 in
PBST. After washing, the enzymatic reaction was devel-
oped with TMB substrate (Sigma-Aldrich, St. Louis,
USA) and stopped by adding 1 M H2SO4.T h eo p t i c a l
density was measured at 450 nm (OD450) in a microtiter
plate reader (Tecan, Groedig, Austria). The apparent
dissociation constant (Kd) of the scFvs was determined
by an indirect ELISA as previously described for full-
length MAbs [30]. Briefly, scFvs were incubated in VLY-
coated plates at concentrations ranging from 50 μg/ml
to 20 ng/ml. The plates were incubated with anti-His5
MAb (Qiagen) and HRP-labelled anti-mouse IgG
(BioRad) and then developed with TMB substrate. The
apparent Kd was calculated from a titration curve and
defined as a molar concentration of scFv corresponding
to the mid-point between maximum OD450 value and
the background.
Hemolytic in vitro assay using human erythrocytes
The use of human erythrocytes from healthy adult volun-
teer following written informed consent was approved by
the Council of the Institute of Biotechnology (Protocol of
30/03/2010, no. 3). In vitro neutralization of VLY hemo-
lytic activity by anti-VLY scFv was analysed as described
previously [30]. Briefly, blood was collected by a veni-
puncture from healthy adult volunteer and anticoagu-
lated with EDTA. Erythrocytes obtained from human
blood were isolated by centrifugation, washed and resus-
pended in sterile PBS. Recombinant VLY (5 ng/ml) was
preincubated for 30 min at RT with serial dilutions of
anti-VLY scFv and added to 1 ml of 1% erythrocyte sus-
p e n s i o ni nP B S .A f t e r1 5m i no fi n c u b a t i o na tR Tt h e
cells were pelleted by centrifugation and the released
hemoglobin was measured at 415 nm in a microplate
reader (Tecan). As a positive control for the neutraliza-
tion assay, VLY pre-incubated with the full-length mur-
ine MAb 9B4 was included. As a negative control, the
erythrocyte suspension was incubated with VLY alone.
The IC50 for the scFvs was defined as the concentration
of the respective recombinant antibody (M) required for
reducing VLY hemolytic activity by 50%.
Cytotoxicity assay using HeLa cell line
Adherent human cervical epithelial HeLa cells (ATCC
Cat. No. CCL-2) were cultivated in RPMI-1640 growth
medium (Biochrom, Berlin, Germany) supplemented
with 10% fetal bovine serum (Biochrom) and antibiotics.
The cells were grown at 37°C and 5% CO2 in 96-well
plates to approx. 70% confluence. After removing growth
medium, the cell monolayer was rinsed twice with
serum-free RPMI-1640 medium and then serum-free
RPMI-1640 medium was added to the cells (50 μl/well).
Recombinant VLY was diluted in serum-free RPMI
media and preincubated with serial dilutions of anti-VLY
scFv for 30 min at RT. The concentration of VLY in each
incubation mixture was 6 μg/ml, the concentrations of
anti-VLY scFv ranged from 1.7 mg/ml to 4 μg/ml. Fifty-
microliters of each mixture were added to the wells with
HeLa cells and the plates were incubated for 1 h at 37°C
and 5% CO2. Thus, after adding the incubation mixture
(50 μl/well) to the culture of HeLa cells (50 μl/well) the
final concentration of VLY in each well was 3 μg/ml. As
a negative control, recombinant VLY at the final concen-
tration of 3 μg/ml was used. As a positive control, VLY
pre-incubated with the full-length neutralizing monoclo-
nal antibody 9B4 (50 μg/ml) was used. Each sample was
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determined by colorimetric assay using 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) staining. Twenty-
microliters of ready-to-use MTS solution (Promega,
Madison, USA) were added to the wells and the plates
were incubated for 2 h at 37°C and 5% CO2. The OD was
measured at 490/630 nm wave length in a microplate
reader (Tecan). Cell viability was also assessed microsco-
pically at magnifications 40× and 100× using microscope
Olympus IX-70 (Olympus, Japan).
Analysis of the stability of anti-VLY scFvs in vitro
In order to evaluate the stability of anti-VLY scFvs, the
purified proteins were stored in 20 mM Tris-HCl (pH
8.0), 50 mM NaCl solution at 3 different concentrations:
0.1, 0.31 and 0.65 mg/ml. Protein samples were stored
at 4°C for 12 months. The stability of the samples stored
at 4°C was analysed at different time points (1, 3, 6, 9,
12 months). Formation of degradation products was
evaluated by SDS-PAGE. The neutralizing activity of the
stored scFvs was determined by the in vitro hemolytic
assay.
Results
Production of anti-VLY scFvs in E.coli
The variable regions of the neutralizing anti-VLY MAbs
9B4 and 23A2 were cloned from the respective hybri-
doma cell lines [30]. The cDNA sequences encoding VH
and VL regions of MAbs 9B4 and 23A2 are deposited in
GenBank under accession numbers JF951747, JF951748,
JF951745 and JF951746. For each hybridoma clone, two
variants of anti-VLY scFvs consisting of either VL-VH
or VH-VL linked with 20 aa-long linker sequence (G4S)4
were constructed. The expression plasmids based on
pET28a(+) vector bearing anti-VLY scFv encoding genes
were transformed into E.coli BL21(DE3) strain. The ana-
lysis of soluble and insoluble fractions of transformed E.
coli cells by SDS-PAGE demonstrated that over 90% of
the recombinant proteins of interest are found in the
insoluble fraction (Figure 1A). The expression levels of
different anti-VLY scFvs determined by SDS-PAGE were
similar and ranged from 20 to 30% of total cell protein
(Figure 1A, Table 1).
The N-terminally hexahistidine-tagged anti-VLY scFvs
representing 27.5 kDa proteins were purified from inclu-
sion bodies by renaturation and subsequent application
of metal-chelate affinity chromatography. Preparations
of purified anti-VLY scFv verified by SDS-PAGE under
reducing conditions represented essentially homogenous
scFvs (Figure 1B). Size exclusion chromatography of
anti-VLY scFvs revealed one major peak with an appar-
ent molecular weight corresponding to monomeric state
of scFv (Figure 1C, Table 1). No fractions corresponding
to the oligomeric forms of scFv were eluted from the
column. This indicated the low tendency of generated
anti-VLY scFvs to form multimeric structures. Thus,
after renaturation and purification steps four variants of
monovalent scFvs derived from the respective hybrido-
mas 9B4 and 23A2 were obtained.
Neutralization of VLY hemolytic activity by anti-VLY scFvs
The ability of anti-VLY scFvs to inhibit the hemolytic
activity of VLY was investigated using human
Figure 1 SDS-PAGE and size-exclusion chromatography of anti-VLY scFv. (A) Detection of expression of anti-VLY scFv 9B4 in E. coli by SDS-
PAGE. Lane 1 - soluble fraction of the cell lysate, lane 2 - insoluble fraction of the cell lysate, lane 3 - total cell lysate. (B) SDS-PAGE of purified
anti-VLY scFvs derived from hybridoma clones 9B4 (lane 1) and 23A2 (lane 2) by metal-chelate affinity chromatography. Lane M - pre-stained
protein molecular weight marker (Thermo Scientific Fermentas). (C) Size-exclusion chromatography of purified anti-VLY scFv 9B4 (variant VL-VH)
on a TSK-gel G2000 SWXL column. The column was calibrated with Gel Filtration LMW Calibration Kit (GE Healthcare, Uppsala, Sweden).
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23A2 have been shown to neutralize the activity of VLY
and prevent the lysis of human erythrocytes in vitro.
The MAb 23A2 was shown to exhibit fair neutralizing
activity (IC50 =4 . 8×1 0
-10 M) while the MAb 9B4
showed the more potent neutralizing activity (IC50 =6 . 7
×1 0
-11 M )[ 3 0 ] .W eh a v ea n a l y s e dt h en e u t r a l i z i n g
potency of different anti-VLY scFv constructs in com-
parison with that of full-length MAbs 9B4 and 23A2.
All purified anti-VLY scFvs were able to neutralize the
hemolytic activity of VLY (Figure 2, Table 2). The IC50
values calculated from concentration-dependent curves
ranged from 3.7 × 10
-8 to 1.5 × 10
-7 M. The anti-VLY
scFvs, both VL-VH and VH-VL variants, derived from
the parental hybridoma clone 9B4 exhibited stronger
neutralizing activity (IC50 =3 . 7×1 0
-8 M and 5.1 × 10
-8
M, respectively) than anti-VLY scFvs derived from
hybridoma clone 23A2 (IC50 =1 . 1×1 0
-7 Ma n d1 . 5×
10
-7 M, respectively). The extent of the neutralizing
potency of different scFvs was in agreement with that of
their parental full-length MAbs (Table 2). The antigen-
binding activities of purified scFvs were investigated by
an indirect ELISA. All scFv variants recognized recombi-
nant VLY immobilized on the plate and showed moder-
ate binding affinities with the apparent Kd 1.1 × 10
-8 to
9.8 × 10
-8 M that was also in line with the affinities of
parental full-length MAbs (Table 2). No VLY-neutraliz-
ing activity was observed when a control scFv derived
from the non-neutralizing hybridoma clone 10G5 was
used (data not shown). A mixture of equal amounts of
two different anti-VLY scFvs showed substantially higher
neutralizing potency on the hemolytic activity of VLY as
compared to single scFv (Figu r e2 ) .T h ea d d i t i v ea c t i o n
of two anti-VLY scFvs on the neutralization of VLY
activity indicates the bivalent manner of the mixture of
anti-VLY scFvs.
Neutralization of VLY cytolytic activity by anti-VLY scFvs
The neutralizing potency of anti-VLY scFvs was assayed
using human cervical epithelial (HeLa) cells. Lysis of
vaginal epithelial cells by VLY is considered to be a key
step in progression of bacterial vaginosis and predispose
to further complications associated with the disease
[3,20]. Thus, inhibition of cytolytic activity of VLY may
Table 1 Expression level and stability of anti-VLY scFvs
Anti-VLY scFv Expression level, % of total cell protein Oligomeric state Activity (%) after 12 months storage at 4°C
scFv 9B4 (VL-VH) 20-30 monomeric 100
scFv 9B4 (VH-VL) 20-30 monomeric 100
scFv 23A2 (VL-VH) 20-30 monomeric 75
scFv 23A2 (VH-VL) 20-30 monomeric 75
Figure 2 Inhibition of VLY-mediated hemolysis of human erythrocytes by anti-VLY scFvs. Erythrocyte lysis was evaluated after incubation
of VLY either with a separate anti-VLY scFv or the mixture of two anti-VLY scFvs (VH-VL variant) derived from hybridoma clones 9B4 and 23A2.
The amounts of anti-VLY scFvs (μg) added to the fixed amount of VLY (5 ng per sample) are indicated on the top of each column.
Pleckaityte et al. BMC Biotechnology 2011, 11:100
http://www.biomedcentral.com/1472-6750/11/100
Page 5 of 9have important physiologic relevance. In a first step the
concentration of VLY required for a complete lysis of
HeLa cells as well as the dynamics of cytolysis were
investigated. For this purpose, the cells were incubated
with increasing VLY concentrations (from 1 ng/ml to
100 μg / m l )a n do b s e r v e dm i c r o s c opically at different
time points (10-60 min). In parallel, the viability of
HeLa cells was measured by colorimetric MTS assay. It
was determined that 2.5 μg/ml of VLY is sufficient to
induce complete lysis of HeLa cells (Figure 3C). The
cytolytic effect of VLY on HeLa cell culture was
observed immediately (10 min) after VLY adding. Thus,
it was demonstrated that the quantities of VLY required
to induce the lysis of HeLa cells are higher than that
required to induce the lysis of human erythrocytes (2.5
μg/ml and 5 ng/ml, respectively). The ability of scFvs
and the respective full-length MAbs to inhibit VLY-
mediated cytolysis of HeLa cells was evaluated by col-
orimetric MTS assay. It was determined that 500 μg/ml
of scFv and 50 μg/ml of full-length antibody 9B4
induced complete neutralization of VLY-mediated cyto-
lysis in HeLa culture (Figure 4). In contrast, the scFv
derived from hybridoma 23A2 did not inhibit VLY cyto-
lytic activity even at the highest concentration used (1
mg/ml), which is explained by its lower affinity and
neutralizing potency (Table 2). In line with these data,
the full-length MAb 23A2 was not able to inhibit VLY
cytolytic activity at concentration of 50 μg/ml and
higher (Figure 4).
Stability of scFvs during long-term storage
The activity of anti-VLY scFvs stored for 12 months at
4°C was tested by determination of their ability to neu-
tralize VLY-mediated lysis of human erythrocytes in
vitro. The appearance of possible degradation products
was analysed by SDS-PAGE. The protein samples stored
at three different concentrations were analyzed at differ-
ent time points. The SDS-PAGE under denaturing con-
ditions did not reveal any degradation products of anti-
VLY scFv (VH-VL and VL-VH variants) derived from
hybridoma clone 9B4 stored for 12 months at 4°C even
at the highest protein concentration (Figure 5A). How-
ever, both variants of scFv derived from hybridoma
clone 23A2 showed minor degradation products when
stored for more that 6 months (Figure 5A). The neutra-
l i z i n gp o t e n c yo fV L Yh e m o l y t i ca c t i v i t yb y2 3 A 2 -
derived scFv declined during storage, while the neutra-
lizing activity of 9B4-derived scFvs remained unchanged
(Figure 5B, Table 1). Thus, VH-VL and VL-VH variants
o f9 B 4 - d e r i v e ds c F vw e r em o r es t a b l ed u r i n gl o n g - t e r m
storage at 4°C as compared to 23A2-derived scFvs.
Discussion
The increasing number of antibiotic resistant bacteria and
the severity of infections upgrade the interest in antibody
therapy against toxins associated with the development of
disease. The high recurrence rate or persistence of infec-
tion, inappropriate or controversial treatment with anti-
biotics, extreme toxicity and potency of the toxins released
from killed bacteria are suggested to be the cases applic-
able for passive immunotherapy [26,29,33]. Recombinant
scFvs either derived from hybridoma cells or produced by
phage display technique remain an attractive alternative to
full-length antibodies because of easier and less costly
manufacture, opportunity of genetic engineering, tissue
penetration and short-circulating half-lives. It was demon-
strated by in vitro and in vivo assays that recombinant
antibodies neutralize the activity of toxins that are highly
diverse in nature and mode of action [23-29]. Hybridoma-
derived scFvs were shown to neutralize the cytolytic
Table 2 Neutralizing activity and affinity of anti-VLY
scFvs and the respective MAbs
Anti VLY scFv and MAb IC50,M K d,M
scFv 9B4 (VL-VH) 3.7 × 10
-8 1.1 × 10
-8
scFv 9B4 (VH-VL) 5.1 × 10
-8 1.5 × 10
-8
scFv 23A2 (VL-VH) 1.1 × 10
-7 9.2 × 10
-8
scFv 23A2 (VH-VL) 1.5 × 10
-7 9.8 × 10
-8
MAb 9B4 6.7 × 10
-11 2.9 × 10
-10
MAb 23A2 4.8 × 10
-10 1.2 × 10
-10
Figure 3 HeLa cell culture after 10 min of incubation with different concentrations of VLY: 0.03 μg/ml (A), 0.3 μg/ml (B), 3 μg/ml (C).
The cells were observed by microscope Olympus IX-70 at magnification 40×.
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[23]. Recently, human scFvs derived from a phage display
library were developed that neutralize the cytotoxicity of
Shiga toxins produced by enterohemorragic E. coli bacteria
[29]. The efficacy of single domain antibodies (VHH) to
neutralize Clostridium difficile toxin A was demonstrated
by the in vitro assay [28]. The ability to neutralize botuli-
num neurotoxin in mice was demonstrated using chimeric
antibody generated by fusion of hybridoma-derived scFv
with human Fc domain [26].
The secreted toxin VLY is known to be the major
virulence factor of G. vaginalis [16,17]. Toxic effect of
VLY is based on its ability to form pores in the cell
membrane causing cell lysis [16,17,19]. Recently, novel
murine MAbs 9B4 and 23A2 against VLY were devel-
oped and characterized as highly efficient in neutralizing
VLY activity in vitro [30]. In the current study, we gen-
erated and characterized four functionally active anti-
VLY scFvs derived from hybridomas 9B4 and 23A2.
Anti-VLY scFvs with hexahistidine residues at the N-ter-
minus were expressed in E. coli and recovered from the
inclusion bodies with subsequent application of metal-
chelate affinity chromatography.
Purified anti-VLY scFvs inhibited VLY-mediated cyto-
lysis with different efficiency that was in line with the
affinity and neutralizing potency of the respective paren-
tal MAbs. The anti-VLY scFvs derived from hybridoma
9B4 exhibited high VLY-neutralizing activity both on
human erythrocytes and cervical epithelial HeLa cells.
Moreover, the 9B4-derived scFvs were shown to be
highly stable during long-term storage at 4°C. Therefore,
this construct may be considered as a promising candi-
date for developing novel therapeutic tools to neutralize
cytotoxic effects of VLY.
Interestingly, VH-VL and VL-VH variants of scFv
showed similar affinity and neutralizing potency. This
suggests that the orientation of variable fragments in the
construct did not influence dramatically the folding and
subsequently the antigen-binding capacity of the scFv.
However, recombinant anti-VLY scFvs did not retain all
the properties of the respective parental MAbs. The
Figure 4 Inhibition of VLY-mediated cytolysis of HeLa cells by
anti-VLY scFvs. HeLa cells were exposed to VLY alone (3 μg/ml) or
VLY (3 μg/ml) preincubated either with scFvs (500 μg/ml) or full-
length MAbs (50 μg/ml). Cell viability was determined by
colorimetric assay using MTS staining. Mean OD490 values (± 2SD)
were calculated from triplicates. The neutralizing activity of each
anti-VLY scFv variant is expressed in % of cytolysis. Complete
cytolysis induced by VLY alone is set 100%.
Figure 5 Stability of anti-VLY scFvs during long-term storage. (A) Analysis of anti-VLY scFvs stored at the concentration of 0.65 mg/ml for
12 months by SDS-PAGE under reducing conditions. Lane 1 - 9B4-derived scFv (variant VH-VL); lane 2 - 23A2-derived scFv (variant VH-VL). Lane
M - pre-stained protein molecular weight marker (Thermo Scientific Fermentas). (B) Testing of anti-VLY scFvs stored at the concentration of 0.65
mg/ml for 1, 6 and 12 months for the ability to neutralize VLY-mediated lysis of human erythrocytes.
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of scFvs as compared to full-length MAbs can be
explained by monovalent binding properties, as purified
anti-VLY scFvs were found predominantly in a mono-
meric form. The avidity could be increased by genera-
tion of recombinant antibodies with multivalent binding
capacity using the scFv multimerization approach or
generation of a fusion with the whole Fc fragment of
human IgG [26,34,35]. The scFvs described in the cur-
rent study is the first example of recombinant single-
chain monovalent antibodies with VLY-neutralizing
activity produced in prokaryote expression system.
Conclusions
We have expressed in E.coli hybridoma-derived scFvs
with VLY-binding activity. Anti-VLY scFvs inhibited
VLY-mediated lysis of human erythrocytes in vitro and
human cervical epithelial HeLa cells. The monovalent
scFvs showed reduced affinity and neutralizing potency
as compared to the respective parental MAbs. The loss
of avidity could be restored by generating scFv con-
structs with multivalent binding properties. G. vaginalis
caused infections continue to be a world-wide problem,
therefore neutralizing recombinant antibodies may pro-
vide novel therapeutic tools useful in the treatment of
BV and other diseases caused by G. vaginalis.
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